|Articles|March 8, 2022
- Pharmaceutical Executive-03-01-2022
- Volume 42
- Issue 3
Pharmaceutical Executive, March 2022 Issue (PDF)
Advertisement
Articles in this issue
over 4 years ago
Pressed Into Action: Measuring Pharma’s Reputation Reversalover 4 years ago
Biopharma in 2021: Big Gains, Volatile Valuesover 4 years ago
The Resilience of R&D: Pharma Posted Record Output in 2021over 4 years ago
New Age of Psychedelicsover 4 years ago
Roads Less Traveledover 4 years ago
Biopharma Stocks, M&A Sputter Amid More Headwindsover 4 years ago
Pandemic Accelerates CTV Ascent: How Pharma Can Benefitover 4 years ago
The Human Factor in Data Security Breachesover 4 years ago
Tapping the Surge in Useful Contingent Labor MarketAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Pharmaceutical Executive Daily: FDA Approves Zanvastro
3
Your Questions Answered: The Biggest Pharma and Biotech Stories This Week
4
FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults
5
